Collaboration: central to our success
Areas of partnering interest
Partnering contacts
Why partner with AstraZeneca?
We partner with academia, governments, peer companies, biotechs, scientific organisations and patient groups to access the best science, stimulate innovation and accelerate delivery of new medicines to target unmet medical need.
From discovery through clinical development, commercialisation and beyond
We’re looking for partners with cutting-edge technologies that can help enhance the quality, effectiveness and productivity of our research and translational capabilities across our therapy areas. We’re also interested in collaborations that leverage key innovations across precision medicine and genomics; artificial intelligence; as well as data and digital technologies, to deliver medicines to patients more efficiently.
Our business development activity takes many forms
Collaborations, in-licensing and acquisitions
with peer companies, biotechs and academia to enhance our portfolio and pipeline across our therapy areas.
Out-licensing and divesting our medicines
that sit outside our main therapy areas and mature brands that can be deployed better by a partner or purchaser. This allows us to maximise the value of our assets while ensuring patients have access to these medicines.
Precision medicine collaborations
to help target our innovative medicines to those patients most likely to benefit.
Joint research centres
with leading academic institutes across the globe.
Open Innovation
Our Open Innovation platform offers scientists anywhere access to a large number of optimised compounds, compound libraries, technologies, data and know-how.
How we evaluate potential collaborations
We assess all projects against our ‘5Rs’ framework to ensure we take forward the most attractive opportunities, regardless of source. This also enables us to provide consistent, objective feedback to potential partners.
Right target
Identifying the right target is critical because a molecule cannot become a medicine if it is modulating the wrong target
Right tissue
Making sure the molecule gets to the tissue where it is needed
Right patient
Selecting the patients who will benefit
Right safety
Ensuring safety with minimal side effects
Right commercial
Defining the appropriate commercial value and future viability
Maximising value through successful, long-term partnerships
We are committed to creating strong, long-term partnerships that help speed the delivery of innovative and life-changing medicines to the people who need them. We also work hard to ensure that both parties receive the greatest possible value from the relationship.
Maximising value through successful, long-term partnerships
We are committed to creating strong, long-term partnerships that help speed the delivery of innovative and life-changing medicines to the people who need them. We also work hard to ensure that both parties receive the greatest possible value from the relationship.
Our R&D Alliance Management and Alliance & Integration Management teams are engaged throughout the deal process. Gaining an early understanding of the strategic, operational and cultural fit between us and our partners helps us structure the partnership governance to be as effective as possible from the start. It also helps to build trust, transparency and strong relationships at all levels.
Our Alliance Management team members are highly experienced professionals with different backgrounds, which enables us to bring the optimal skill-set to any collaboration. A dedicated member from one of our Alliance Management teams is assigned around the contracting stage and remains your key contact throughout the collaboration.
Based on our work across a wide range of complex business and scientific collaborations, we have developed industry-leading processes and tools that ensure smooth and efficient interactions.
In acquisitions, divestments and spinoffs, our Alliance Management teams act as the central hub for key functional areas across the business, ensuring an efficient integration or transition of the products involved.
Veeva ID: Z4-68873
Date of preparation: September 2024